Traynor Capital Management, Inc. Vertex Pharmaceuticals Inc Transaction History
Traynor Capital Management, Inc.
- $1.4 Billion
- Q2 2025
A detailed history of Traynor Capital Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Traynor Capital Management, Inc. holds 11,675 shares of VRTX stock, worth $4.53 Million. This represents 0.37% of its overall portfolio holdings.
Number of Shares
11,675
Previous 11,044
5.71%
Holding current value
$4.53 Million
Previous $5.35 Million
2.93%
% of portfolio
0.37%
Previous 0.46%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,810Shares Held
232MCall Options Held
1.51MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$11.1 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$9.3 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.26 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$5.64 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.57 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $99.5B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...